CorMedix Reports Positive Interim Results from Real-World DefenCath Study in Hemodialysis Patients

Reuters

2025/12/18

CorMedix Reports Positive Interim Results from Real-World DefenCath Study in Hemodialysis Patients

CorMedix Inc. announced interim results from its ongoing real-world evidence study of DefenCath, conducted in collaboration with U.S. Renal Care $(USRC)$ in adult hemodialysis patients with central venous catheters. The study began following the outpatient commercial launch of DefenCath in July 2024 and is designed to prospectively assess the rates of catheter-related bloodstream infections (CRBSI) and related hospitalizations over a two-year period. Interim data from approximately 7,000 patients who received at least one dose of DefenCath in the first year indicate a reduction in serious infections and hospitalizations. Additional secondary outcomes, such as missed treatment sessions, antibiotic use, and tPA utilization, are also being evaluated, with further results expected in the future. CorMedix is using this data in ongoing discussions with customers and payers, including Medicare Advantage plans, to support broader access and reimbursement for DefenCath.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604271) on December 18, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2592517906"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592517906\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592517906?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592517906","market":"us","top_or_hot":-1,"title":"CorMedix Reports Positive Interim Results from Real-World DefenCath Study in Hemodialysis Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CorMedix Reports Positive Interim Results from Real-World DefenCath Study in Hemodialysis Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CRMD\">CorMedix Inc.</a> announced interim results from its ongoing real-world evidence study of DefenCath, conducted in collaboration with U.S. Renal Care <a href=\"https://laohu8.com/S/USRC\">$(USRC)$</a> in adult hemodialysis patients with central venous catheters. The study began following the outpatient commercial launch of DefenCath in July 2024 and is designed to prospectively assess the rates of catheter-related bloodstream infections (CRBSI) and related hospitalizations over a two-year period. Interim data from approximately 7,000 patients who received at least one dose of DefenCath in the first year indicate a reduction in serious infections and hospitalizations. Additional secondary outcomes, such as missed treatment sessions, antibiotic use, and tPA utilization, are also being evaluated, with further results expected in the future. CorMedix is using this data in ongoing discussions with customers and payers, including Medicare Advantage plans, to support broader access and reimbursement for DefenCath.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604271) on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CorMedix Reports Positive Interim Results from Real-World DefenCath Study in Hemodialysis Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorMedix Reports Positive Interim Results from Real-World DefenCath Study in Hemodialysis Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CorMedix Reports Positive Interim Results from Real-World DefenCath Study in Hemodialysis Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CRMD\">CorMedix Inc.</a> announced interim results from its ongoing real-world evidence study of DefenCath, conducted in collaboration with U.S. Renal Care <a href=\"https://laohu8.com/S/USRC\">$(USRC)$</a> in adult hemodialysis patients with central venous catheters. The study began following the outpatient commercial launch of DefenCath in July 2024 and is designed to prospectively assess the rates of catheter-related bloodstream infections (CRBSI) and related hospitalizations over a two-year period. Interim data from approximately 7,000 patients who received at least one dose of DefenCath in the first year indicate a reduction in serious infections and hospitalizations. Additional secondary outcomes, such as missed treatment sessions, antibiotic use, and tPA utilization, are also being evaluated, with further results expected in the future. CorMedix is using this data in ongoing discussions with customers and payers, including Medicare Advantage plans, to support broader access and reimbursement for DefenCath.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604271) on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL42Tb9J:1","article_id":"2592517906","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592517906","pubTimestamp":1766062936,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CorMedix Inc. announced interim results from its ongoing real-world evidence study of DefenCath, conducted in collaboration with U.S. Renal Care  in adult hemodialysis patients with central venous catheters. The study began following the outpatient commercial launch of DefenCath in July 2024 and is designed to prospectively assess the rates of catheter-related bloodstream infections  and related hospitalizations over a two-year period. Interim data from approximately 7,000 patients who received at least one dose of DefenCath in the first year indicate a reduction in serious infections and hospitalizations. Additional secondary outcomes, such as missed treatment sessions, antibiotic use, and tPA utilization, are also being evaluated, with further results expected in the future. CorMedix is using this data in ongoing discussions with customers and payers, including Medicare Advantage plans, to support broader access and reimbursement for DefenCath.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","CRMD":"CorMedix Inc.","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","BK4007":"制药","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4588":"碎股","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"CorMedix报告血液透析患者真实世界DefenCath研究的积极中期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"CRMD":0.9},"content_text":"CorMedix Reports Positive Interim Results from Real-World DefenCath Study in Hemodialysis Patients\n    \n\nCorMedix Inc. announced interim results from its ongoing real-world evidence study of DefenCath, conducted in collaboration with U.S. Renal Care $(USRC)$ in adult hemodialysis patients with central venous catheters. The study began following the outpatient commercial launch of DefenCath in July 2024 and is designed to prospectively assess the rates of catheter-related bloodstream infections (CRBSI) and related hospitalizations over a two-year period. Interim data from approximately 7,000 patients who received at least one dose of DefenCath in the first year indicate a reduction in serious infections and hospitalizations. Additional secondary outcomes, such as missed treatment sessions, antibiotic use, and tPA utilization, are also being evaluated, with further results expected in the future. CorMedix is using this data in ongoing discussions with customers and payers, including Medicare Advantage plans, to support broader access and reimbursement for DefenCath.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CorMedix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9604271) on December 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}